Latest News
Disc Medicine, Inc.
- Why is Disc Medicine stock sliding today? By Investing.com
- Disc Medicine prices $450 million stock offering at $75/share By Investing.com
- Disc Medicine's late-stage win clears path for approval of sun-allergy pill
- Disc Medicine seeks $350M after positive Phase 3 result for lead drug
- Disc Medicine launches $350 million stock offering By Investing.com
- Disc Medicine stock jumps 38% on positive Phase 3 trial and analyst upgrade
- Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
- Disc Medicine's rare disease drug succeeds in late-stage trial
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drug
- Why is Disc Medicine stock surging today? By Investing.com
- Disc Medicine reports positive phase 3 trial results for EPP drug
- After FDA rejection, Disc Medicine's 'sun allergy' drug hits home run in Phase 3
Headlines from the last 30 days, linking to the original publishers. See all market news →